BD-1047
BD-1047: A σ1 Subtype Sigma Receptor Antagonist
BD-1047 is a pharmacologically significant compound, recognized for its antagonistic action on the σ1 subtype of sigma receptors. Preclinical evidence has illuminated its potential antipsychotic effects, while also suggesting a role in neuropathic pain management. This positions BD-1047 at an interesting nexus in the field of neuropsychopharmacology.
Introduction
Sigma receptors, initially mistaken for a subtype of opioid receptors, are now known to represent unique non-opioid receptors. The σ1 subtype, in particular, is deeply implicated in modulating neurotransmission and is therefore a focal point for drug discovery and neurobiological research.
Mechanism of Action
BD-1047, classified as a sigma receptor antagonist, exhibits its primary pharmacological action by binding to and inhibiting the σ1 subtype. This action has important repercussions for neurotransmitter systems and neural signaling processes[1].
Potential Therapeutic Applications
- Antipsychotic Properties: Animal models have shown that BD-1047 can modulate behaviors and responses associated with psychosis, which suggests it may have antipsychotic properties[2].
- Neuropathic Pain Management: The drug's action on the σ1 receptor also hints at potential benefits in addressing neuropathic pain, a challenging clinical symptom often resistant to conventional treatments[3].
Preclinical and Clinical Development
While BD-1047 has shown promise in preclinical settings, the trajectory from laboratory findings to clinical applications is intricate. Detailed pharmacokinetic and safety profiling will be imperative as BD-1047 progresses through the developmental pipeline.
Concluding Remarks
BD-1047, as a selective antagonist of the σ1 sigma receptor subtype, introduces new horizons in the study and potential treatment of psychiatric disorders and neuropathic pain conditions. Continued research will undoubtedly shed more light on its full spectrum of actions and therapeutic potential.
References
- ↑ Matsumoto RR, Bowen WD, Tom MA, Vo VN, Truong DD, De Costa BR. Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism. Eur J Pharmacol. 1995;280(3):301-310.
- ↑ Ishima T, Fujita Y, Hashimoto K. Interaction of new antidepressants with sigma-1 receptor chaperones and their potentiation of neurite outgrowth in PC12 cells. Eur J Pharmacol. 2014;727:167-173.
- ↑ Romero L, Zamanillo D, Nadal X, et al. Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. Br J Pharmacol. 2012;166(8):2289-2306.
References
Transform your life with W8MD's budget GLP-1 injections from $125.
W8MD offers a medical weight loss program to lose weight in Philadelphia. Our physician-supervised medical weight loss provides:
- Most insurances accepted or discounted self-pay rates. We will obtain insurance prior authorizations if needed.
- Generic GLP1 weight loss injections from $125 for the starting dose.
- Also offer prescription weight loss medications including Phentermine, Qsymia, Diethylpropion, Contrave etc.
NYC weight loss doctor appointments
Start your NYC weight loss journey today at our NYC medical weight loss and Philadelphia medical weight loss clinics.
- Call 718-946-5500 to lose weight in NYC or for medical weight loss in Philadelphia 215-676-2334.
- Tags:NYC medical weight loss, Philadelphia lose weight Zepbound NYC, Budget GLP1 weight loss injections, Wegovy Philadelphia, Wegovy NYC, Philadelphia medical weight loss, Brookly weight loss and Wegovy NYC
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD